Taiwan’s Caliway Biopharmaceuticals Co. Ltd. said it secured more than $100 million in an oversubscribed capital raise to advance CBL-514, its lead asset for subcutaneous fat reduction nearing phase III studies.

Biopharmas raising money in public or private financings, including: Betterlife, Biora, Eterna, Pivotal Life.

Biopharmas raising money in public or private financings, including: AC Immune, Awakn, Eterna, Fractyl, Syndax, Totus.

Biopharmas raising money in public or private financings, including: Amazentis, Cadenza, Ocular, Vandria, Veru.

Biopharmas raising money in public or private financings, including: Algernon, Encellin, Evolveimmune, Mitorx, Tome.

Japan-California startup Shinobi Therapeutics Inc. has emerged from stealth mode with a $51 million series A round to advance its first off-the-shelf induced pluripotent stem cell (iPS)-T cell therapy against glypigan-3 (GPC3)-positive cancers toward the clinic.

Biopharmas raising money in public or private financings, including: 89bio, Antabio, Bicara, Carmot, Coya, Freya, OM, Roche, Shinobi.

Biopharmas raising money in public or private financings, including: Eyepoint, Immunoprecise, In8bio, Prelude, Springworks, Zafrens.

Following a strategic transaction with Graphite Bio Inc., Kamau Therapeutics is emerging from stealth with sickle cell treatment nulabeglogene autogedtemcel (nula-cel). Kamau received an option to acquire all of Graphite’s genome editing assets, including a platform technology that integrates precision DNA repair using homology directed repair and CRISPR/Cas9, as well as the autologous CRISPR/Cas9 gene corrected CD34+ cell product nula-cel, which offers a potential cure for sickle cell disease derived from the patient's cells.